Lipella pharmaceuticals reports positive topline phase 2a results for lp-310 in the treatment of oral lichen planus

Lp-310 treatment demonstrates clinically meaningful reductions in pain, ulceration, and inflammation across all key metrics findings highlight favorable safety profile and tolerability of twice-daily oral rinse multicenter phase 2a trial advancing to higher treatment dose with recruitment expected to conclude the first half of 2025 lipella leadership to present findings at bio ceo & investor conference on tuesday, february 11, 2025, at 2:30 p.m. est pittsburgh, feb. 11, 2025 (globe newswire) -- lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella,” “our,” “us,” or the “company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today shared topline analysis of its phase 2a multicenter dose-ranging trial examining lp-310, a liposomal-tacrolimus oral rinse formulation of lp-10 being developed to treat oral lichen planus (“olp”).
LIPO Ratings Summary
LIPO Quant Ranking